Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
GYRE
$8.4
$
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Next Earnings
2026-02-25
Beta
7.048
Average Volume
Market Cap
Last Dividend
CIK
0001124105
ISIN
US4037831033
CUSIP
403783103
CEO
Ping Zhang
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
579
IPO Date
2006-04-12
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX) | ImmunityBio (NASDAQ: IBRX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Insider and Institutional Ownership 8.6% of ImmunityBio shares are | Defense World | 2026-02-02 01:44:52 |
| Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting | Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing for Hydronidone and priority review eligibility, subject to formal approval. Gyre Pharmaceuticals plans to submit an NDA in the first half of 2026 and conduct a confirmatory clinical trial to support full approval in China. | GlobeNewsWire | 2026-01-05 07:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 8-K | 2026-01-05 | 2026-01-05 | View Filing |
| 10-Q | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-11-07 | 2025-11-06 | View Filing |
| 8-K | 2025-09-10 | 2025-09-10 | View Filing |
| 4 | 2025-08-26 | 2025-08-26 | View Filing |
| 3 | 2025-08-26 | 2025-08-26 | View Filing |
| 8-K | 2025-08-22 | 2025-08-22 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-06 | 2025-06-05 | View Filing |
| 4 | 2025-05-29 | 2025-05-29 | View Filing |
| 4 | 2025-05-28 | 2025-05-28 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 8-K | 2025-05-23 | 2025-05-23 | View Filing |
| 424B5 | 2025-05-23 | 2025-05-23 | View Filing |
| 424B5 | 2025-05-22 | 2025-05-22 | View Filing |
| 8-K | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-14 | 2025-05-14 | View Filing |
| 4 | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-05-09 | 2025-05-08 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-25 | 2025-04-25 | View Filing |
| ARS | 2025-04-22 | 2025-04-22 | View Filing |
| DEFA14A | 2025-04-21 | 2025-04-21 | View Filing |
| DEF 14A | 2025-04-21 | 2025-04-21 | View Filing |
| 4 | 2025-04-18 | 2025-04-18 | View Filing |
| 4 | 2025-03-25 | 2025-03-25 | View Filing |
| 4 | 2025-03-21 | 2025-03-21 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| 10-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-17 | 2025-03-17 | View Filing |
| 4 | 2025-03-13 | 2025-03-13 | View Filing |
| 4 | 2025-03-11 | 2025-03-11 | View Filing |
| 4 | 2025-03-11 | 2025-03-11 | View Filing |
| 4 | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 8-K | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-06 | 2025-02-06 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-01-31 | 2025-01-31 | View Filing |
| 4 | 2025-01-29 | 2025-01-29 | View Filing |
| 4 | 2025-01-27 | 2025-01-27 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-21 | 2025-01-21 | View Filing |
| 4 | 2025-01-16 | 2025-01-16 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4/A | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 3 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2024-12-30 | 2024-12-30 | View Filing |
| 4 | 2024-12-26 | 2024-12-26 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-19 | 2024-12-19 | View Filing |
| 8-K | 2024-11-27 | 2024-11-27 | View Filing |
| 424B5 | 2024-11-27 | 2024-11-27 | View Filing |
| EFFECT | 2024-11-25 | 2024-11-25 | View Filing |
| CORRESP | 2024-11-20 | 2024-11-20 | View Filing |
| UPLOAD | 2024-11-20 | 2024-11-20 | View Filing |
| S-3 | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-12 | View Filing |
| SC 13D | 2024-09-06 | 2024-09-06 | View Filing |
| SC 13D | 2024-09-06 | 2024-09-06 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 4 | 2024-08-16 | 2024-08-16 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Liquidity Sweep Strategy | 23.61% | 1.4 | 5 | 0.51 | 0.6 | 30.08 |
| Volume Gap | 20.64% | 1.07 | 39 | 0.48 | 0.57 | 27.11 |
| Larry Williams PercentR Strategy | 20.01% | 1.85 | 16 | 0.74 | 108 | 26.48 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxx% | xxx | x | xxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | x |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |